Vaxcyte, Inc. (NASDAQ:PCVX) Shares Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. raised its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 23.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,428 shares of the company's stock after purchasing an additional 4,962 shares during the quarter. China Universal Asset Management Co. Ltd.'s holdings in Vaxcyte were worth $2,163,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Blue Trust Inc. lifted its position in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock worth $42,000 after purchasing an additional 93 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Vaxcyte by 5.2% in the third quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the company's stock valued at $252,000 after acquiring an additional 110 shares in the last quarter. CIBC Asset Management Inc raised its holdings in shares of Vaxcyte by 3.6% in the third quarter. CIBC Asset Management Inc now owns 3,136 shares of the company's stock valued at $358,000 after acquiring an additional 110 shares in the last quarter. Riverview Trust Co bought a new stake in shares of Vaxcyte in the third quarter valued at about $27,000. Finally, Amalgamated Bank raised its holdings in shares of Vaxcyte by 8.6% in the third quarter. Amalgamated Bank now owns 4,081 shares of the company's stock valued at $466,000 after acquiring an additional 322 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors.

Insider Transactions at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the firm's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $92.45, for a total transaction of $1,386,750.00. Following the completion of the transaction, the chief executive officer now directly owns 450,301 shares of the company's stock, valued at approximately $41,630,327.45. This trade represents a 3.22 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $88.78, for a total transaction of $710,240.00. Following the sale, the chief financial officer now directly owns 109,491 shares in the company, valued at $9,720,610.98. The trade was a 6.81 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 70,982 shares of company stock worth $6,341,485. Insiders own 3.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on PCVX shares. Needham & Company LLC restated a "buy" rating and issued a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, November 6th. The Goldman Sachs Group started coverage on Vaxcyte in a report on Friday, December 20th. They issued a "buy" rating and a $135.00 price objective for the company. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Vaxcyte in a report on Wednesday, November 6th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $145.71.

Vaxcyte Trading Up 3.0 %

Shares of PCVX stock traded up $2.58 during trading hours on Wednesday, reaching $89.10. 488,948 shares of the company's stock were exchanged, compared to its average volume of 1,193,993. Vaxcyte, Inc. has a 1 year low of $58.10 and a 1 year high of $121.06. The stock has a market cap of $11.11 billion, a PE ratio of -19.44 and a beta of 0.98. The stock's fifty day moving average price is $87.37 and its two-hundred day moving average price is $94.45.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts' consensus estimates of ($1.10) by $0.27. During the same period in the previous year, the business posted ($0.91) EPS. On average, equities analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.